Data set: Genome scale CRISPR Cas9a knockout screen reveals genes that controls glioblastoma susceptibility to the alkylating agent temozolomide (TMZ).

Glioblastoma is the deadliest of all primary brain tumor with a very poor survival outcome. Alkylating agent such as temozolomide is used as a mainstay drug used in treating of glioblastoma patients including radiation, tumor treating field and surgery. However, this drug offers little to no benefit for the glioblastoma patients. Hence, the objective of the generation of this data is to understand and unravel genes that controls  glioblastoma susceptibility and resistance to temozolomide using an unbiased genome scale CRISPR Cas9a knockout screen